Other languages Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-05-28 pm EDT			5-day change	1st Jan Change
40.49 ^USD	-1.82%		-6.62%	-21.09%

May. 28	Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	MT
May. 27	Bristol Myers: will present data on schizophrenia	CF

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	May. 28
Bristol Myers : présentera des données sur la schizophrénie	May. 27
Bristol Myers : présente plus de 130 études à l'ASCO	May. 27
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment	May. 23
USA: BMS et Sanofi condamnés pour défaut d'information sur le Plavix	May. 22
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million	May. 22
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines	May. 22
Bristol Myers : stratégie sur 10 ans pour les pays pauvres	May. 22
Bristol-Myers Squibb Invests in NeoPhore	May. 22
Bristol Myers : campagne nationale sur la schizophrénie	May. 21
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab	May. 21
Bristol Myers : date butoir fixée pour Opdivo sous-cutané	May. 21
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (Nivolumab and Hyaluronidase)	May. 21
EE.UU. - Valores a seguir en Wall Street (actualizado)	May. 16
Bristol Myers Squibb : Chubb, Cisco, Walmart... les valeurs à suivre à Wall Street -	May. 16
Bristol Myers Squibb: approbation accélérée pour le traitement anti-lymphome	May. 16
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma	May. 16
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma	May. 15
US FDA approves expanded use of Bristol's cancer cell therapy	May. 15
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint	May. 10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST